NovaBridge Biosciences Reports 77% Response Rate in HER2-Negative Gastric Cancer Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: NASDAQ.COM
- Significant Efficacy: NovaBridge's Phase 1b combination study of givastomig with nivolumab and chemotherapy in HER2-negative metastatic gastric cancer demonstrated an overall response rate of 77% at 8 mg/kg, indicating the potential to transform first-line treatment options.
- Extended Survival: The median progression-free survival reached 16.9 months at the 8 mg/kg dose, with a six-month landmark progression-free survival rate of 73%, providing patients with a longer survival period and enhancing the clinical value of the therapy.
- Good Safety Profile: The combination therapy exhibited a safety profile comparable to current standard-of-care treatments, demonstrating good tolerability, which may position it as a viable option for future therapies and improve patient treatment experiences.
- Stock Price Surge: NovaBridge's shares rose over 11% in pre-market trading after closing at $4.37, up 2.34%, reflecting the market's positive reaction to the study results and potentially attracting more investor interest in its future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBP
Wall Street analysts forecast NBP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.570
Low
7.00
Averages
8.00
High
9.00
Current: 1.570
Low
7.00
Averages
8.00
High
9.00
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NovaBridge Receives FDA Fast Track Designation for Givastomig
- FDA Fast Track Designation: NovaBridge Biosciences' Givastomig has received FDA Fast Track Designation, aimed at accelerating the development of treatments for HER2-negative metastatic gastric cancer patients, particularly those with tumors expressing both CLDN18.2 and PD-L1, highlighting the company's potential in addressing unmet medical needs.
- Clinical Trial Results: In a Phase 1b study, Givastomig combined with nivolumab and chemotherapy demonstrated compelling efficacy and favorable tolerability, with deep and durable responses exceeding historical benchmarks, indicating its potential as a first-in-class CLDN18.2-directed therapy.
- Future Development Plans: NovaBridge expects to initiate a registrational Phase 3 trial as early as Q4 2026, evaluating Givastomig in combination with nivolumab and chemotherapy in first-line HER2-negative metastatic gastroesophageal adenocarcinomas, further advancing its market application.
- Stock Market Performance: Over the past year, NBP's stock has fluctuated between $1.46 and $6.79, closing at $1.47 on Monday, down 1.34%, but rising 7.48% to $1.58 in pre-market trading, reflecting market interest in its drug development progress.
See More
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig
- FDA Fast Track Designation: NovaBridge Biosciences announced that its novel CLDN18.2 x 4-1BB bispecific antibody, givastomig, has received Fast Track Designation from the FDA, aimed at accelerating the development of treatments for HER2-negative advanced gastroesophageal adenocarcinomas, showcasing the company's innovative potential in biopharmaceuticals.
- Clinical Trial Plans: The registrational Phase 3 trial is expected to commence in the fourth quarter of 2026, marking a significant milestone in the company's drug development process and potentially addressing unmet medical needs in oncology.
- Preliminary Data Support: Phase 1b trial data demonstrated robust efficacy and favorable tolerability for givastomig in combination with immunochemotherapy, further solidifying its position as a leading CLDN18.2-directed therapy for gastric cancer.
- Positive Market Reaction: In Tuesday's pre-market trading, NBP's stock price rose by 10.20% to $1.62, reflecting investor optimism regarding the FDA designation and its potential market prospects.
See More
NovaBridge Receives FDA Fast Track Designation for Givastomig
- FDA Fast Track Designation: NovaBridge announced that its drug givastomig has received Fast Track Designation from the FDA, aimed at treating patients with HER2-negative advanced gastroesophageal adenocarcinomas, marking significant progress in addressing unmet medical needs.
- Clinical Trial Data Support: Phase 1b trials demonstrated compelling efficacy and tolerability for givastomig in combination with immunochemotherapy, with response rates significantly improved compared to historical benchmarks, indicating its potential as a first-line treatment.
- Registration Trial Plans: The company expects to initiate a registrational Phase 3 clinical trial as early as Q4 2026, with Fast Track Designation facilitating a more efficient development and review process, enhancing market access efficiency.
- Global Collaborative Development: Givastomig is being developed in partnership with ABL Bio, with NovaBridge as the lead party sharing global rights (excluding Greater China and South Korea), showcasing its strategic positioning in the global market.
See More
I-Mab Biopharma Reports FY GAAP EPS
- Earnings Report: I-Mab Biopharma reported a FY GAAP EPS of -$0.48, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position: As of December 31, 2025, the company had $210.8 million in cash, cash equivalents, and short-term investments, with the current cash position expected to support operations through 2028, ensuring financial stability in the coming years.
- Clinical Data Discussion: NovaBridge Biosciences discussed Phase 2a clinical data and development plans for VIS-101 in wet age-related macular degeneration, highlighting ongoing R&D investments that could lay the groundwork for future product launches.
- Market Reaction Outlook: The financial data and clinical advancements from I-Mab Biopharma may influence market expectations regarding its future growth potential, prompting investors to monitor subsequent R&D outcomes and financial improvements.
See More
NovaBridge Successfully Transforms into a Global Biotech Platform
- Clinical Trial Progress: NovaBridge's givastomig demonstrates a 75% objective response rate in gastric cancer trials, with a median progression-free survival of 16.9 months among 52 evaluable patients, indicating strong market competitiveness.
- FDA Accelerated Approval Potential: Givastomig confirmed potential eligibility for the Accelerated Approval pathway at an FDA Type B meeting, with a registrational Phase 3 trial expected to initiate in Q4 2026, further advancing its commercialization prospects.
- Strong Financial Position: As of December 31, 2025, NovaBridge reported $210.8 million in cash, expected to support operations through 2028, showcasing the company's robust financial capacity for R&D and market expansion.
- Executive Team Expansion: NovaBridge has expanded its Board of Directors and executive team by appointing several industry experts to drive growth, reflecting its strategic positioning in the global biotech sector and confidence in future developments.
See More
NOVABRIDGE ANNOUNCES 2025 FULL YEAR FINANCIAL RESULTS AND BUSINESS UPDATE
Financial Results: Novabridge reports its full-year financial results for 2025, highlighting key performance metrics and overall financial health.
Business Update: The report provides a comprehensive business update, detailing recent developments and strategic initiatives undertaken by the company.
See More
NovaBridge Receives FDA Fast Track Designation for Givastomig
- FDA Fast Track Designation: NovaBridge Biosciences' Givastomig has received FDA Fast Track Designation, aimed at accelerating the development of treatments for HER2-negative metastatic gastric cancer patients, particularly those with tumors expressing both CLDN18.2 and PD-L1, highlighting the company's potential in addressing unmet medical needs.
- Clinical Trial Results: In a Phase 1b study, Givastomig combined with nivolumab and chemotherapy demonstrated compelling efficacy and favorable tolerability, with deep and durable responses exceeding historical benchmarks, indicating its potential as a first-in-class CLDN18.2-directed therapy.
- Future Development Plans: NovaBridge expects to initiate a registrational Phase 3 trial as early as Q4 2026, evaluating Givastomig in combination with nivolumab and chemotherapy in first-line HER2-negative metastatic gastroesophageal adenocarcinomas, further advancing its market application.
- Stock Market Performance: Over the past year, NBP's stock has fluctuated between $1.46 and $6.79, closing at $1.47 on Monday, down 1.34%, but rising 7.48% to $1.58 in pre-market trading, reflecting market interest in its drug development progress.
See More
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig
- FDA Fast Track Designation: NovaBridge Biosciences announced that its novel CLDN18.2 x 4-1BB bispecific antibody, givastomig, has received Fast Track Designation from the FDA, aimed at accelerating the development of treatments for HER2-negative advanced gastroesophageal adenocarcinomas, showcasing the company's innovative potential in biopharmaceuticals.
- Clinical Trial Plans: The registrational Phase 3 trial is expected to commence in the fourth quarter of 2026, marking a significant milestone in the company's drug development process and potentially addressing unmet medical needs in oncology.
- Preliminary Data Support: Phase 1b trial data demonstrated robust efficacy and favorable tolerability for givastomig in combination with immunochemotherapy, further solidifying its position as a leading CLDN18.2-directed therapy for gastric cancer.
- Positive Market Reaction: In Tuesday's pre-market trading, NBP's stock price rose by 10.20% to $1.62, reflecting investor optimism regarding the FDA designation and its potential market prospects.
See More
NovaBridge Receives FDA Fast Track Designation for Givastomig
- FDA Fast Track Designation: NovaBridge announced that its drug givastomig has received Fast Track Designation from the FDA, aimed at treating patients with HER2-negative advanced gastroesophageal adenocarcinomas, marking significant progress in addressing unmet medical needs.
- Clinical Trial Data Support: Phase 1b trials demonstrated compelling efficacy and tolerability for givastomig in combination with immunochemotherapy, with response rates significantly improved compared to historical benchmarks, indicating its potential as a first-line treatment.
- Registration Trial Plans: The company expects to initiate a registrational Phase 3 clinical trial as early as Q4 2026, with Fast Track Designation facilitating a more efficient development and review process, enhancing market access efficiency.
- Global Collaborative Development: Givastomig is being developed in partnership with ABL Bio, with NovaBridge as the lead party sharing global rights (excluding Greater China and South Korea), showcasing its strategic positioning in the global market.
See More
I-Mab Biopharma Reports FY GAAP EPS
- Earnings Report: I-Mab Biopharma reported a FY GAAP EPS of -$0.48, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position: As of December 31, 2025, the company had $210.8 million in cash, cash equivalents, and short-term investments, with the current cash position expected to support operations through 2028, ensuring financial stability in the coming years.
- Clinical Data Discussion: NovaBridge Biosciences discussed Phase 2a clinical data and development plans for VIS-101 in wet age-related macular degeneration, highlighting ongoing R&D investments that could lay the groundwork for future product launches.
- Market Reaction Outlook: The financial data and clinical advancements from I-Mab Biopharma may influence market expectations regarding its future growth potential, prompting investors to monitor subsequent R&D outcomes and financial improvements.
See More
NovaBridge Successfully Transforms into a Global Biotech Platform
- Clinical Trial Progress: NovaBridge's givastomig demonstrates a 75% objective response rate in gastric cancer trials, with a median progression-free survival of 16.9 months among 52 evaluable patients, indicating strong market competitiveness.
- FDA Accelerated Approval Potential: Givastomig confirmed potential eligibility for the Accelerated Approval pathway at an FDA Type B meeting, with a registrational Phase 3 trial expected to initiate in Q4 2026, further advancing its commercialization prospects.
- Strong Financial Position: As of December 31, 2025, NovaBridge reported $210.8 million in cash, expected to support operations through 2028, showcasing the company's robust financial capacity for R&D and market expansion.
- Executive Team Expansion: NovaBridge has expanded its Board of Directors and executive team by appointing several industry experts to drive growth, reflecting its strategic positioning in the global biotech sector and confidence in future developments.
See More
NOVABRIDGE ANNOUNCES 2025 FULL YEAR FINANCIAL RESULTS AND BUSINESS UPDATE
Financial Results: Novabridge reports its full-year financial results for 2025, highlighting key performance metrics and overall financial health.
Business Update: The report provides a comprehensive business update, detailing recent developments and strategic initiatives undertaken by the company.
See More
